Your email has been successfully added to our mailing list.

×
0 0.00146877314243396 0.000493705257960899 0.00148111577388287 0.00246852628980485 0.00265366576154023 0.00615773882991844 0.00543075783757094
Stock impact report

Biotech: Halozyme CEO explains what it looks for in M&A targets [Yahoo! Finance Canada]

Halozyme Therapeutics, Inc. (HALO) 
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: halozyme.com/investors/default.aspx
M&A activity in the biotech industry has been forecasted to accelerate in 2026. Dr. Helen Torley, the CEO and president of Halozyme, explains to Julie Hyman the characteristics that the company looks for in biotech companies that are potential acquisition targets. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts Recommended Stories Show less Read more
Impact Snapshot
Event Time:
HALO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for HALO alerts
Opt-in for
HALO alerts

from News Quantified
Opt-in for
HALO alerts

from News Quantified